Volume 11 Issue 6
Nov.  2020
Turn off MathJax
Article Contents
HUANG Ping, FENG Bian-ying, MU Di, ZHOU Hao, YAO Zu-de, MAN Qiu-hong. Characteristics and Development of Platform Construction of Clinical Biobank in China[J]. Medical Journal of Peking Union Medical College Hospital, 2020, 11(6): 754-757. doi: 10.3969/j.issn.1674-9081.2020.06.021
Citation: HUANG Ping, FENG Bian-ying, MU Di, ZHOU Hao, YAO Zu-de, MAN Qiu-hong. Characteristics and Development of Platform Construction of Clinical Biobank in China[J]. Medical Journal of Peking Union Medical College Hospital, 2020, 11(6): 754-757. doi: 10.3969/j.issn.1674-9081.2020.06.021

Characteristics and Development of Platform Construction of Clinical Biobank in China

doi: 10.3969/j.issn.1674-9081.2020.06.021
More Information
  • Corresponding author: MAN Qiu-hong  Tel: 86-13161508773, E-mail:Manqiuhong307@163.com
  • Received Date: 2019-06-05
  • Accepted Date: 2019-07-17
  • Available Online: 2019-07-23
  • Publish Date: 2020-11-30
  • Medical research urgently needs to integrate and share a large number of valuable biological samples and data resources to solve difficult problems in major diseases. In medical institutions, the clinical biological sample database plays the role of service-supporting platform for scientific research, which integrates limited biological samples and corresponding data to provide resource guarantee for the exploration of disease occurrence, development, transition, diagnosis, treatment, drug development and health prevention. In this paper, the characteristics and contents of standardized construction of clinical biobank platforms in China, the collaborative management mode of public management platforms, and the operation content and quality control of resource platforms were emphatically expounded. The purpose of this paper is to promote the standardized system construction of platforms of clinical biological sample database in China.
  • loading
  • [1] Coppola L, Cianflone A, Grimaldi AM, et al. Biobanking in health care: evolution and future directions[J]. J Transl Med, 2019, 17:172. doi:  10.1186/s12967-019-1922-3
    [2] Quinlan PR, Groves M, Jordan LB, et al. The Informatics Challenges Facing Biobanks: A Perspective from a United Kingdom Biobanking Network[J]. Biopreserv Biobank, 2015, 13: 363-370. doi:  10.1089/bio.2014.0099
    [3] 满秋红, 于农, 闫飞, 等.我国生物样本库建设现状与未来发展的思考[J].中国医药生物技术, 2018, 13: 289-293. doi:  10.3969/j.issn.1673-713X.2018.04.001
    [4] 徐艳, 樊萍, 胡迅.生物样本库建设的关键问题及解决策略[J].华西医学, 2018, 33: 651-654.
    [5] 郜恒骏, 杜莉利, 张小燕, 等.生物样本库发展的现状、机遇与挑战[J].协和医学杂志, 2018, 9: 172-176. doi:  10.3969/j.issn.1674-9081.2018.02.013
    [6] 翟培军, 李军燕, 胡冬梅, 等.生物样本库国际认可和标准化发展与前景[J].中华临床实验室管理电子杂志, 2017, 5: 6-8. doi:  10.3877/cma.j.issn.2095-5820.2017.01.003
    [7] Haga SB, Beskow LM. Ethical, legal, and social implica-tions of biobanks for genetics research[J]. Adv Genet, 2008, 60: 505-544. doi:  10.1016/S0065-2660(07)00418-X
    [8] Ollier W, Sprosen T, Peakman T. UK Biobank: from concept to reality[J]. Pharmacogenomics, 2005, 6: 639-646. doi:  10.2217/14622416.6.6.639
    [9] Fearn P, Michels C, Meagher K, et al. 2012 International Society for Biological and Environmental Repositories Informatics Working Group: survey results and conclusions[J]. Biopreserv Biobank, 2013, 11: 64-66. doi:  10.1089/bio.2012.1115
    [10] Vaught J. Biobanking Comes of Age: The Transition to Biospecimen Science[J]. Annu Rev Pharmacol Toxicol, 2016, 56: 211-228. doi:  10.1146/annurev-pharmtox-010715-103246
    [11] Quinlan PR, Gardner S, Groves M, et al. A Data-Centric Strategy for Modern Biobanking[J]. Adv Exp Med Biol, 2015, 864: 165-169.
    [12] De Souza YG, Greenspan JS.Biobanking past, present and future: responsibilities and benefits[J]. AIDS, 2013, 27: 303-312. doi:  10.1097/QAD.0b013e32835c1244
    [13] Zhu S, Shen M, Qiu X, et al. Ethical management guidelines for the shanghai disease-based biobank network[J]. Biopreserv Biobank, 2015, 13: 8-12. doi:  10.1089/bio.2014.0087
    [14] Baker M. Biorepositories: Building better biobanks[J]. Nature, 2012, 486: 141-146. doi:  10.1038/486141a
    [15] Zamboni WC, Torchilin V, Patri AK, et al.Best practices in cancer nanotechnology: perspective from NCI nanotechnology alliance[J]. Clin Cancer Res, 2012, 18: 3229-3241. doi:  10.1158/1078-0432.CCR-11-2938
    [16] 郭丹, 杨文航, 徐英春.临床生物样本库信息系统建设与发展[J].协和医学杂志, 2018, 9: 81-86. doi:  10.3969/j.issn.1674-9081.2018.01.015
    [17] Rush A, Byrne JA. Quality and reporting practices in an Australian cancer biobank cohort[J]. Clin Biochem, 2016, 49: 492-497. doi:  10.1016/j.clinbiochem.2015.12.007
    [18] Betsou F, Sobel ME. The ISBER Biorepository proficiency testing program: two successful years already, and new features to come[J]. Biopreserv Biobank, 2013, 11: 255-256. doi:  10.1089/bio.2013.1143
    [19] Vaught J, Campbell LD, Betsou F, et al. The ISBER Best Practices: Insight from the Editors of the Third Edition[J]. Biopreserv Biobank, 2012, 10: 76-78. doi:  10.1089/bio.2012.1024
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Article Metrics

    Article views (934) PDF downloads(62) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return